Nektar Therapeutics (NKTR) Research & Development (2010 - 2026)

Nektar Therapeutics has reported Research & Development for 17 years, with the latest figure at $35.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 17.06% year-over-year to $35.7 million; the trailing twelve-month figure through Mar 2026 stood at $122.5 million (down 1.17% YoY), and the FY2025 full-year result was $117.3 million, down 2.96% from the prior year.
• Research & Development for Q1 2026 stood at $35.7 million, up from $29.7 million in the prior quarter.
• The five-year high for Research & Development was $107.3 million in Q1 2022, with the low at $24.1 million in Q3 2023.
• Average Research & Development over 5 years is $35.7 million, with a median of $29.9 million recorded in 2023.
• Year-over-year, Research & Development tumbled 71.59% in 2023 and soared 45.54% in 2024.
• Tracing NKTR's Research & Development over 5 years: stood at $34.7 million in 2022, then retreated by 13.81% to $29.9 million in 2023, then declined by 4.0% to $28.7 million in 2024, then gained by 3.36% to $29.7 million in 2025, then grew by 20.09% to $35.7 million in 2026.
• The last three Research & Development figures came in at $35.7 million (Q1 2026), $29.7 million (Q4 2025), and $27.3 million (Q3 2025), per Business Quant data.

Peer Comparison